Opposing effects on endothelium and smooth muscle may explain why vascular effects of ATP and UTP can vary (35). While ATP induces vasodilation, UTP promotes vasoconstriction in rabbit ear artery and mouse aortic rings (3; 18; 56) . Other studies have reported that ATP and UTP can cause vasodilation, vasoconstriction, or both, depending on species, vessel type, location within the vascular tree, and/or route of administration (5; 7; 14; 15; 36; 37; 39).
We recently obtained in vivo evidence for a physiological role of P2Y 2 receptors in blood pressure regulation by demonstrating that P2Y 2 -/-mice have salt-resistant arterial hypertension (41). In the kidney P2Y 2 receptors have an inhibitory influence on Na + and fluid reabsorption (33; 44; 54; 60). Activation of P2Y 2 receptors in the apical membrane of the aldosterone-sensitive distal nephron (ASDN) inhibits the open probability (P o ) of the epithelial sodium channel (ENaC), an effect mediated by activation of phospholipase C (31; 41). In addition we showed that an increase in the apical release of ATP and/or UTP, which activates P2Y 2 receptors, mediates the suppression of ENaC P o in response to increasing salt intake, thereby contributing to NaCl homeostasis and blood pressure regulation (32). We also found that lack of P2Y 2 receptors is associated with increased activity of Na-2Cl-K-cotransporter isoform 2 (NKCC2) in the thick ascending limb and increased water reabsorption in the collecting duct (41).
To further define the in vivo role of P2Y 2 receptors and potentially that of P2Y 4 receptor activation, in the current studies we compared the effects of systemic administration of a P2Y 2/4 receptor agonist (INS45973) on blood pressure and renal excretion in wild-type (WT) and P2Y 2 -/-mice. We find that such administration acts via P2Y 2 receptor activation to lower blood pressure, an effect that is independent of endothelial NO, and to inhibit renal Na 
Materials and Methods
Animal experiments were conducted according to the protocols reviewed and approved by the Institutional Animal Care and Use Committee of the Veterans Affairs San Diego Healthcare System. Generation of P2Y 2 -/-mice has been described earlier (11). P2Y 2 -/-mice were back-crossed to 129Sv/J for a total of 7 generations.
Heterozygous animals from the final backcross were bred to each other so as to yield P2Y 2 -/-and littermate WT mice. Genotyping was done by polymerase chain reaction from ear tissue DNA and use of primers, as previously described (41). Endothelial NO synthase knockout mice (eNOS-/-), which are on a C57Bl/6J background, were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Adult male mice were used for all experiments. Figure 1 . Application of vehicle had no effect on blood pressure or heart rate in either genotype. Acute application of INS45973 in WT dose-dependently and rapidly (within 15 s of starting infusion) decreased blood pressure (maximum response -35±2 mmHg, Figures 1 and 2) . Notably, blood pressure began to increase towards basal levels while the bolus was being administered. In contrast, INS45973 induced a dose-dependent, rapid (within 15 s of starting infusion) increase in blood pressure in In eNOS-/-mice, basal mean arterial blood pressure and heart rate were 131±3 mmHg and 479±17 min 
Discussion
Little is known about the responses in blood pressure and renal function to acute systemic activation of P2Y 2 and P2Y 4 receptors. Here we used INS45973, a UTP analog and P2Y 2/4 receptor agonist, to gain new insights regarding these responses. To our knowledge these are the first studies to provide direct in vivo evidence that acute activation of P2Y 2 receptors decreases blood pressure in a manner that is independent of endothelium-derived NO. Notably, the absence of P2Y 2 receptors unmasks an acute increase in blood pressure in response to INS45973, an effect that may be mediated by P2Y 4 receptor activation. Both the decrease in blood pressure in WT mice and the increase in P2Y 2 -/-mice likely result from changes in peripheral resistance since the effects occurred within seconds of agonist application and in the absence of changes in heart rate.
Our findings are in agreement with previous studies that showed a dosedependent decrease in arterial blood pressure in anesthetized mice with acute i.v. administration of ATP and UTP (50). The authors used pharmacological agents to conclude that P2X 1 , P2Y 1 (both not activated by UTP) and P2Y 4 receptors did not significantly contribute to this response and surmised that P2Y 2 receptors potentially mediated vasodilation. Consistent with this finding, Guns et al. (8) showed that ATPevoked relaxation was impaired in the aorta of P2Y 2 -/-mice. By contrast, ATP-and UTP-evoked vasorelaxation was intact in aortas of P2Y 4 -/-mice (7). Conclusions from these latter two studies, however, were hampered by the fact that the aorta is not considered a resistance vessel.
How does P2Y 2 receptor activation cause vasodilation in WT mice? It has been shown that endothelial P2Y 2 receptors stimulate the synthesis and release of NO (34-37). We thus studied the effect of INS45973 in eNOS-/-mice, which have an endothelial NO-independent pathway. We found that eNOS-/-mice show the same rapid blood pressure decrease in response to INS45973 as do WT mice, results that imply a role for the synthesis and release of endothelium-derived hyperpolarization factor (EDHF).
Based on results from in vitro studies, it has been speculated that EDHF is a major mediator for dilation of the peripheral vascular bed by nucleotides (24; 27). Moreover, UTP-mediated reduction of vascular resistance in the human forearm is resistant to Changes in blood pressure cannot explain these effects since P2Y 2 receptor activation reduced blood pressure which, by itself, is expected to be antinatriuretic. 
Perspectives and Significance
The current results show that in vivo stimulation of P2Y 2 receptors provokes an acute decrease in blood pressure, which is independent of endothelial NO. In contrast, in the absence of P2Y 2 receptors, the acute blood pressure increase in response to a Maximal responses in blood pressure (A) and heart rate (B) to acute bolus application of INS45973 in wild-type (WT, n=7) and P2Y 2 knockout mice (P2Y 2 -/-, n=8). In WT mice, application of INS45973 dose-dependently decreased blood pressure whereas in P2Y 2 -/-mice blood pressure increased. In both genotypes heart rate was unaffected. Error bars are covered. *P < 0.05 vs. WT same dose, § P < 0.05 vs. vehicle. 
